0.47
-3.89%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PZ Cormay
Its shares trade on GPW under the ticker CRM.WA. It has been listed since 20 August 2008. In the fiscal year to 31 December 2025, it reported revenue of PLN 96.3m and a net loss of PLN 4.2m. At that date it held total assets of PLN 88.2m and shareholders' equity of PLN 45.9m.
PZ Cormay SA engages in the manufacture of diagnostic reagents and laboratory equipment. The company is headquartered in Lomianki, Woj. Mazowieckie. The company went IPO on 2008-08-20. The firm is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. The company offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 20 Aug 2008
- Employees
- 222
- Website
- cormay.com ↗
Leadership
Pay as last reported
- Mr. Flavio FinolettoPresident of the Management BoardPLN 110,000
- Mr. Wojciech SuchowskiVice Chairman of the Management BoardPLN 360,000
- Mr. Witold RebaczChief Accounting Officer
- Mr. Kamil GewartowskiMember of the Supervisory Board
- Mr. Tomasz MarkowskiMember of the Supervisory BoardPLN 42,000
- Mr. Marcin MurawskiMember of the Supervisory Board
- Mr. Marcin SieczekMember of the Supervisory Board
- Mr. Blazej DowgielskiInvestor Relations Contact Officer, since 2017
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PZ Cormay SA manufactures diagnostic reagents and laboratory equipment.
- The company employs 222 full-time employees.
- It offers a range of products including biochemical analyzers and hematological analyzers.
Weaknesses
- The company's IPO was in 2008, indicating a long-standing presence but potential outdated infrastructure.
- The firm's product range is limited to specific medical fields like clinical chemistry and hematology.
- The company's website is provided but no additional details about its digital presence are given.
Opportunities
- The acquisition by Orphee SA in 2014 may lead to restructuring and improved operations.
- The company's focus on diagnostic reagents and equipment aligns with growing healthcare demands.
- Expansion into new markets for biochemical rapid tests and devices could be a growth area.
Threats
- The company's reliance on specific medical fields may limit growth opportunities.
- The untrusted source mentions a restructuring plan, which could indicate instability.
- The lack of recent data beyond 2014 may affect current market positioning.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.